APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infantile Spasms Therapeutics

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Selected research

Market Analysis & Forecast

Global Infantile Spasms Therapeutics Market Analysis and Forecast 2026-2032

21 December 2025197 pages

Choose your research edition.

Industry ResearchInfantile Spasms Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Infantile Spasms Therapeutics Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Infantile Spasms Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infantile Spasms Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Infantile Spasms Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.

In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.

Read the full market overview

Report Includes

This report presents an overview of global market for Infantile Spasms Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Infantile Spasms Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Infantile Spasms Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Infantile Spasms Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Infantile Spasms Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Infantile Spasms Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Infantile Spasms Therapeutics Segment by Company

Mallinckrodt

H. Lundbeck

Insys Therapeutics

Orphelia Pharma

Valerion Therapeutics

Catalyst Pharmaceuticals

Anavex Life Sciences

Retrophin

GW Pharmaceuticals

Infantile Spasms Therapeutics Segment by Type

Oral

Injection

Infantile Spasms Therapeutics Segment by Application

Hospital

Clinic

Other

Infantile Spasms Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Infantile Spasms Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Infantile Spasms Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infantile Spasms Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Infantile Spasms Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. Global Infantile Spasms Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Infantile Spasms Therapeutics Industry Trends Table 9. Infantile Spasms Therapeutics Industry Drivers Table 10. Infantile Spasms Therapeutics Industry Opportunities and Challenges Table 11. Infantile Spasms Therapeutics Industry Restraints Table 12. Global Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Infantile Spasms Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Infantile Spasms Therapeutics Market Share by Region (2021-2026) Table 15. Global Infantile Spasms Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Infantile Spasms Therapeutics Market Share by Region (2027-2032) Table 17. Global Infantile Spasms Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Infantile Spasms Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Infantile Spasms Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Infantile Spasms Therapeutics Key Players Headquarters & Area Served Table 21. Global Infantile Spasms Therapeutics Players, Product Type & Application Table 22. Global Infantile Spasms Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Infantile Spasms Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Infantile Spasms Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Infantile Spasms Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Infantile Spasms Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Infantile Spasms Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Infantile Spasms Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Infantile Spasms Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Mallinckrodt Company Information Table 36. Mallinckrodt Business Overview Table 37. Mallinckrodt Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Mallinckrodt Infantile Spasms Therapeutics Product Portfolio Table 39. Mallinckrodt Recent Development Table 40. H. Lundbeck Company Information Table 41. H. Lundbeck Business Overview Table 42. H. Lundbeck Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. H. Lundbeck Infantile Spasms Therapeutics Product Portfolio Table 44. H. Lundbeck Recent Development Table 45. Insys Therapeutics Company Information Table 46. Insys Therapeutics Business Overview Table 47. Insys Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio Table 49. Insys Therapeutics Recent Development Table 50. Orphelia Pharma Company Information Table 51. Orphelia Pharma Business Overview Table 52. Orphelia Pharma Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio Table 54. Orphelia Pharma Recent Development Table 55. Valerion Therapeutics Company Information Table 56. Valerion Therapeutics Business Overview Table 57. Valerion Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio Table 59. Valerion Therapeutics Recent Development Table 60. Catalyst Pharmaceuticals Company Information Table 61. Catalyst Pharmaceuticals Business Overview Table 62. Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio Table 64. Catalyst Pharmaceuticals Recent Development Table 65. Anavex Life Sciences Company Information Table 66. Anavex Life Sciences Business Overview Table 67. Anavex Life Sciences Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio Table 69. Anavex Life Sciences Recent Development Table 70. Retrophin Company Information Table 71. Retrophin Business Overview Table 72. Retrophin Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Retrophin Infantile Spasms Therapeutics Product Portfolio Table 74. Retrophin Recent Development Table 75. GW Pharmaceuticals Company Information Table 76. GW Pharmaceuticals Business Overview Table 77. GW Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio Table 79. GW Pharmaceuticals Recent Development Table 80. North America Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Infantile Spasms Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Infantile Spasms Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Infantile Spasms Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Infantile Spasms Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 94. China Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 95. China Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 96. China Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 97. China Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Infantile Spasms Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Infantile Spasms Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Infantile Spasms Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Infantile Spasms Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Infantile Spasms Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Infantile Spasms Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Infantile Spasms Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Infantile Spasms Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Infantile Spasms Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Infantile Spasms Therapeutics Image Figure 2. Global Infantile Spasms Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infantile Spasms Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. Global Infantile Spasms Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Infantile Spasms Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Infantile Spasms Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Infantile Spasms Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Infantile Spasms Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Infantile Spasms Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Infantile Spasms Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Infantile Spasms Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Infantile Spasms Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Infantile Spasms Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Infantile Spasms Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Infantile Spasms Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Infantile Spasms Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Infantile Spasms Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Infantile Spasms Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Infantile Spasms Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Infantile Spasms Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Infantile Spasms Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Infantile Spasms Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Infantile Spasms Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Infantile Spasms Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Infantile Spasms Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Infantile Spasms Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Infantile Spasms Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Infantile Spasms Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Infantile Spasms Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Infantile Spasms Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Infantile Spasms Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Infantile Spasms Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Infantile Spasms Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Infantile Spasms Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Infantile Spasms Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Mallinckrodt
  • H. Lundbeck
  • Insys Therapeutics
  • Orphelia Pharma
  • Valerion Therapeutics
  • Catalyst Pharmaceuticals
  • Anavex Life Sciences
  • Retrophin
  • GW Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Infantile Spasms Therapeutics Market by Type
  3. 1.2.1 Global Infantile Spasms Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.3 Infantile Spasms Therapeutics Market by Application
  7. 1.3.1 Global Infantile Spasms Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Infantile Spasms Therapeutics Market Dynamics
  1. 2.1 Infantile Spasms Therapeutics Industry Trends
  2. 2.2 Infantile Spasms Therapeutics Industry Drivers
  3. 2.3 Infantile Spasms Therapeutics Industry Opportunities and Challenges
  4. 2.4 Infantile Spasms Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Infantile Spasms Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Infantile Spasms Therapeutics Growth Trends by Region
  3. 3.2.1 Global Infantile Spasms Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Infantile Spasms Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Infantile Spasms Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Infantile Spasms Therapeutics Revenue by Players
  2. 4.1.1 Global Infantile Spasms Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Infantile Spasms Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Infantile Spasms Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Infantile Spasms Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Infantile Spasms Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Infantile Spasms Therapeutics Players, Product Type & Application
  8. 4.5 Global Infantile Spasms Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Infantile Spasms Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Infantile Spasms Therapeutics Tier 1, Tier 2, and Tier 3
5 Infantile Spasms Therapeutics Market Size by Type
  1. 5.1 Global Infantile Spasms Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Infantile Spasms Therapeutics Revenue Market Share by Type (2021-2032)
6 Infantile Spasms Therapeutics Market Size by Application
  1. 6.1 Global Infantile Spasms Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Infantile Spasms Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Mallinckrodt
  2. 7.1.1 Mallinckrodt Company Information
  3. 7.1.2 Mallinckrodt Business Overview
  4. 7.1.3 Mallinckrodt Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
  6. 7.1.5 Mallinckrodt Recent Developments
  7. 7.2 H. Lundbeck
  8. 7.2.1 H. Lundbeck Company Information
  9. 7.2.2 H. Lundbeck Business Overview
  10. 7.2.3 H. Lundbeck Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
  12. 7.2.5 H. Lundbeck Recent Developments
  13. 7.3 Insys Therapeutics
  14. 7.3.1 Insys Therapeutics Company Information
  15. 7.3.2 Insys Therapeutics Business Overview
  16. 7.3.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
  18. 7.3.5 Insys Therapeutics Recent Developments
  19. 7.4 Orphelia Pharma
  20. 7.4.1 Orphelia Pharma Company Information
  21. 7.4.2 Orphelia Pharma Business Overview
  22. 7.4.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
  24. 7.4.5 Orphelia Pharma Recent Developments
  25. 7.5 Valerion Therapeutics
  26. 7.5.1 Valerion Therapeutics Company Information
  27. 7.5.2 Valerion Therapeutics Business Overview
  28. 7.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
  30. 7.5.5 Valerion Therapeutics Recent Developments
  31. 7.6 Catalyst Pharmaceuticals
  32. 7.6.1 Catalyst Pharmaceuticals Company Information
  33. 7.6.2 Catalyst Pharmaceuticals Business Overview
  34. 7.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
  36. 7.6.5 Catalyst Pharmaceuticals Recent Developments
  37. 7.7 Anavex Life Sciences
  38. 7.7.1 Anavex Life Sciences Company Information
  39. 7.7.2 Anavex Life Sciences Business Overview
  40. 7.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
  42. 7.7.5 Anavex Life Sciences Recent Developments
  43. 7.8 Retrophin
  44. 7.8.1 Retrophin Company Information
  45. 7.8.2 Retrophin Business Overview
  46. 7.8.3 Retrophin Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
  48. 7.8.5 Retrophin Recent Developments
  49. 7.9 GW Pharmaceuticals
  50. 7.9.1 GW Pharmaceuticals Company Information
  51. 7.9.2 GW Pharmaceuticals Business Overview
  52. 7.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
  54. 7.9.5 GW Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Infantile Spasms Therapeutics Revenue (2021-2032)
  2. 8.2 North America Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Infantile Spasms Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Infantile Spasms Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Infantile Spasms Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Infantile Spasms Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Infantile Spasms Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Infantile Spasms Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Infantile Spasms Therapeutics Revenue by Country
  11. 8.6.1 North America Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Infantile Spasms Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Infantile Spasms Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Infantile Spasms Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Infantile Spasms Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Infantile Spasms Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Infantile Spasms Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Infantile Spasms Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Infantile Spasms Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Infantile Spasms Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Infantile Spasms Therapeutics Revenue by Country
  11. 9.6.1 Europe Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Infantile Spasms Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Infantile Spasms Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Infantile Spasms Therapeutics Revenue (2021-2032)
  2. 10.2 China Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Infantile Spasms Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Infantile Spasms Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Infantile Spasms Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Infantile Spasms Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Infantile Spasms Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Infantile Spasms Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Infantile Spasms Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Infantile Spasms Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Infantile Spasms Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Infantile Spasms Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Infantile Spasms Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Infantile Spasms Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Infantile Spasms Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Infantile Spasms Therapeutics Revenue by Country
  11. 11.6.1 Asia Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Infantile Spasms Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Infantile Spasms Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Infantile Spasms Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Infantile Spasms Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Infantile Spasms Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Infantile Spasms Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Infantile Spasms Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Infantile Spasms Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Infantile Spasms Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Infantile Spasms Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Infantile Spasms Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Infantile Spasms Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Infantile Spasms Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Infantile Spasms Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Infantile Spasms Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst